v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Operating expenses:        
Research and development, net (includes $10 and $140 for the three months ended June 30, 2026 and 2025, respectively; and $10 and $165 for the six months ended June 30, 2026 and 2025, respectively, of related party research and development reimbursement) $ (6,582) $ (6,745) $ (8,524) $ (13,499)
Selling, general and administrative (includes $65 and $44 for the three months ended June 30, 2026 and 2025, respectively; and $153 and $88 for the six months ended June 30, 2026 and 2025, respectively, of related party expenses) (6,379) (4,657) (10,928) (11,025)
Total operating expenses (12,961) (11,402) (19,452) (24,524)
Loss from operations (12,961) (11,402) (19,452) (24,524)
Other income (expense), net:        
Other income, net 523 833 289 1,085
Total other income (expenses), net 1,620 833 (464) 1,085
Loss before income taxes (11,341) (10,569) (19,916) (23,439)
Income tax expense 0 0 0 0
Net loss (11,341) (10,569) (19,916) (23,439)
Net loss attributable to common stockholders - basic (11,341) (10,569) (19,916) (23,439)
Net loss attributed to common stockholders - diluted $ (16,079) $ (10,569) $ (24,654) $ (23,439)
Net loss per share attributable to common stockholders – basic (in usd per share) $ (0.61) $ (0.57) $ (1.07) $ (1.27)
Net loss per share attributable to common stockholders – diluted (in usd per share) $ (0.85) $ (0.57) $ (1.32) $ (1.27)
Weighted-average common stock outstanding - basic (in shares) 18,594,006 18,423,699 18,571,685 18,486,699
Weighted-average common stock outstanding - diluted (in shares) 18,934,279 18,423,699 18,742,761 18,486,699
Other comprehensive loss:        
Foreign currency translation adjustments $ (76) $ (182) $ (374) $ (174)
Comprehensive loss (11,417) (10,751) (20,290) (23,613)
Related Party        
Operating expenses:        
Research and development, net (includes $10 and $140 for the three months ended June 30, 2026 and 2025, respectively; and $10 and $165 for the six months ended June 30, 2026 and 2025, respectively, of related party research and development reimbursement) (10) (140) (10) (165)
Selling, general and administrative (includes $65 and $44 for the three months ended June 30, 2026 and 2025, respectively; and $153 and $88 for the six months ended June 30, 2026 and 2025, respectively, of related party expenses) (65) (44) (153) (88)
Other income (expense), net:        
Financing costs related to issuance of convertible promissory notes 0 0 (37) 0
Change in fair value of convertible promissory notes (2,384) 0 (3,791) 0
Nonrelated Party        
Other income (expense), net:        
Change in fair value of convertible promissory notes (964) 0 (1,264) 0
Series B-1 and Series D redeemable convertible preferred stock warrants        
Other income (expense), net:        
Change in fair value of warrant liabilities for Series B-1 and Series D redeemable convertible preferred stock (293) 0 (399) 0
Series B-1 and Series D redeemable convertible preferred stock warrants | Related Party        
Other income (expense), net:        
Change in fair value of warrant liabilities for Series B-1 and Series D redeemable convertible preferred stock (229) 0 (262) 0
Warrants for Series A        
Other income (expense), net:        
Change in fair value of warrant liabilities for Series B-1 and Series D redeemable convertible preferred stock $ 4,738 $ 0 $ 4,738 $ 0